Background: The safety and feasibility of using 1-month dual antiplatelet therapy (DAPT)
followed by P2Y 12 inhibitor monotherapy for patients after percutaneous coronary …

Several studies have demonstrated the safety and feasibility of short (3–6 months) and very
short duration (< 2 months) dual antiplatelet therapy (DAPT) in patients with a durable …

Objective To investigate the efficacy and safety of 6-month and 12-month oral dual-
antiplatelet therapy This work was supported by the National Key Technology Research and …

Background: This study evaluated the safety of 3-month dual antiplatelet therapy (DAPT)
after implantation of a bioresorbable polymer sirolimus-eluting stent (BP-SES) and …

Background: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention is associated with increased bleeding, despite a reduced incidence of ischemic …

Importance P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12
inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for …

Objective This study sought to compare the clinical outcomes of 6‐month versus 12‐month
dual antiplatelet therapy (DAPT) in patients receiving multiple biodegradable polymer …

Background—There are no reports on a large-scale randomized trial exploring optimal dual
antiplatelet therapy (DAPT) duration after biodegradable polymer sirolimus-eluting stent …

Background: Limited data are available on short-term dual antiplatelet therapy (DAPT) after
percutaneous coronary intervention using third-generation drug-eluting stents with ultrathin …

Newer generation durable polymer drug-eluting stents (DP-DES) and biodegradable
polymer DES (BP-DES) have similar efficacy with dual-antiplatelet therapy (DAPT) duration …